# SPECIALTY GUIDELINE MANAGEMENT

## **COMETRIQ** (cabozantinib)

### POLICY

#### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

#### A. FDA-Approved Indication

Treatment of progressive, metastatic medullary thyroid cancer (MTC).

- B. <u>Compendial Uses</u>
  - 1. Follicular, Hürthle cell, and papillary thyroid carcinoma
  - 2. Non-small cell lung cancer with RET gene arrangements

All other indications are considered experimental/investigational and not medically necessary.

#### **II. DOCUMENTATION**

Submission of RET gene rearrangement documentation is necessary to initiate the prior authorization review for the indication of non-small cell lung cancer.

#### **III. CRITERIA FOR INITIAL APPROVAL**

#### A. Thyroid carcinoma

Authorization of 12 months may be granted for treatment of thyroid carcinoma when any of the following criteria are met:

- 1. Member has follicular, Hürthle cell, or papillary thyroid carcinoma that is not amenable to radioactive iodine (RAI) therapy.
- 2. Member has medullary thyroid carcinoma.

#### B. Non-small cell lung cancer (NSCLC)

Authorization of 12 months may be granted for treatment of recurrent, advanced, or metastatic NSCLC with RET gene rearrangements.

#### IV. CONTINUATION OF THERAPY

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in Section III when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

#### V. REFERENCES

#### Cometriq 1854-A SGM P2021.docx

© 2020 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.



- 1. Cometriq [package insert]. South San Francisco, CA: Exelixis; October 2020.
- 2. The NCCN Drugs & Biologics Compendium® © 2020 National Comprehensive Cancer Network, Inc. Available at: https://www.nccn.org. Accessed November 6, 2020.

Cometriq 1854-A SGM P2021.docx

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.



© 2020 CVS Caremark. All rights reserved.